Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7559824 | 0.83 | KCNN4 (0.51) | CYP2B6ALDH1A1MAPTCHRM3NPSR1 | |
| SCHEMBL10982647 | 0.78 | CHRM3 (0.46) | PIN1ALDH1A1MAPTCHRM3CHRM2 | |
| SCHEMBL7646732 | 0.74 | PIN1 (0.54) | PIN1ALDH1A1MAPTCHRM3NPSR1 | |
| SCHEMBL4525774 | 0.73 | CYP2B6 (0.47) | CYP2B6MAPTCHRM3CHRM2CYP2D6 | |
| SCHEMBL1647761 | 0.72 | KCNN4 (0.62) | PIN1ALDH1A1MAPTCHRM3NPSR1 | |
| SCHEMBL5639395 | 0.72 | PIN1 (0.56) | PIN1ALDH1A1MAPTCHRM3NPSR1 | |
| SCHEMBL26039065 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPTCYP2D6TSHR | |
| SCHEMBL27916287 | 0.71 | CES1 (0.56) | PIN1ALDH1A1MAPTCHRM3NPSR1 | |
| SCHEMBL2128439 | 0.71 | CYP2B6 (0.50) | CYP2B6CHRM3NPSR1CHRM2CHRM4 | |
| SCHEMBL2127685 | 0.71 | CYP2B6 (0.50) | CYP2B6CHRM3NPSR1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797694-B2 | TRIARYLMETHANE DERIVATIVES HAVING INHIBITORY ACTIVITY ON AN INTERMEDIATE CONDUCTANCE CALCIUM ION ACTIVATED POTASSIUM CHANNEL (IKCA) | POSEIDON PHARMACEUTICALS A/S (DK) | 2004-09-28 | — | — | US | claimed |
| US-20020065247-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | NEUROSEARCH A/S (DK) | 2002-05-30 | — | — | US | claimed |
| EP-1181016-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OFIMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2002-02-27 | — | — | EP | claimed |
| WO-2000069439-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | claimed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065247-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNN3 | CYP2B6 3761/4885PIN1 2990/4885ALDH1A1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.